Leading in innovation by following the science

Click here to view a larger version of this image
This figure was adapted with permission from Cell, Vol 100, Hanahan and Weinberg, The Hallmarks of Cancer, pp 57-70, Copyright Elsevier (2000).
While there are many distinct types of cancer, there are believed to be 6 essential alterations to normal cell physiology, which together define the progression of most human malignancies.1
Our goal at Genentech, a member of the Roche Group, is to investigate and develop innovative therapies that target the biologic mechanisms that give rise to cancer, with the hope of extending the lives of patients. Our scientists are dedicated to defining the molecular basis of cancer and to translating this knowledge into the development of novel biologic and small-molecule agents that target the ability of cancer cells to grow and spread.
|
Self-sufficiency in growth signals:
|
|
|
Evading apoptosis:
|
|
|
Sustained angiogenesis:
|
|
|
Limitless potential for replication:
|
|
|
Tissue invasion and metastasis:
|
|
|
Insensitivity to antigrowth signals:
|